LITHIUM CARBONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lithium Carbonate, and what generic alternatives are available?
Lithium Carbonate is a drug marketed by Able, Alembic Ltd, Apotex Inc, Glenmark Generics, Hetero Labs Ltd Iii, Hikma, Mylan, Usl Pharma, Watson Labs, Alembic, Glenmark Pharms Inc, Heritage Pharma, Hikma Intl Pharms, Mylan Pharms Inc, Unique, Pfizer, and Sun Pharm Inds Inc. and is included in twenty-nine NDAs.
The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lithium Carbonate
A generic version of LITHIUM CARBONATE was approved as lithium carbonate by HIKMA on January 29th, 1982.
Summary for LITHIUM CARBONATE
US Patents: | 0 |
Applicants: | 17 |
NDAs: | 29 |
Finished Product Suppliers / Packagers: | 21 |
Raw Ingredient (Bulk) Api Vendors: | 133 |
Clinical Trials: | 98 |
Patent Applications: | 101 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LITHIUM CARBONATE |
What excipients (inactive ingredients) are in LITHIUM CARBONATE? | LITHIUM CARBONATE excipients list |
DailyMed Link: | LITHIUM CARBONATE at DailyMed |
Recent Clinical Trials for LITHIUM CARBONATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Second Xiangya Hospital of Central South University | Phase 1/Phase 2 |
First Affiliated Hospital of Chongqing Medical University | Phase 1/Phase 2 |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 |
Pharmacology for LITHIUM CARBONATE
Drug Class | Mood Stabilizer |